KARDIOLOGIE LIBEREC s.r.o.

Verified siteinfo

Czechia Papirova 525/10, Liberec II-Nove Mesto, 460 01 Liberec, Czechia

2 trials recruiting
Arteriosclerosis · Cardiac failure · Myocardial infarction
Adult patients

About Specializations

KARDIOLOGIE LIBEREC s.r.o. in Liberec, Czechia specialises in clinical trials of conditions such as Arteriosclerosis, Cardiac failure, Myocardial infarction, Obesity, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiology

The medical center is at the forefront of cardiology research, focusing on innovative treatments for chronic heart failure. Through rigorous clinical trials, the center is exploring the efficacy of novel therapeutic agents like AZD5462, aiming to improve patient outcomes and quality of life.

Chronic Heart Failure
Innovative Drug Therapies
Patient Quality of Life

By conducting dose-ranging studies, the center contributes significantly to understanding the optimal therapeutic strategies for managing heart failure, thereby setting new standards in cardiovascular care.

Arrhythmology

Specializing in arrhythmology, the center is dedicated to advancing the treatment of atrial fibrillation. Through comparative studies of drugs like abelacimab and rivaroxaban, the institution is pioneering efforts to enhance the safety and tolerability of anticoagulant therapies.

Atrial Fibrillation
Anticoagulant Safety
Therapeutic Comparisons

The center's research is pivotal in reducing bleeding risks associated with anticoagulation, thereby improving the therapeutic landscape for patients with irregular heart rhythms.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Papirova 525/10, Liberec II-Nove Mesto460 01 LiberecCzechia

Open in maps ↗

Recruiting now: 2 trials
Conditions studied: 7
Partner status: Verified site

More sites in Liberec Czechia

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

9 clinical trials

Arteriosclerosis

Recruiting

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational

Czechia

Participants:18–64 years · 65+ years
Sponsor:AstraZeneca AB

Contact Research Centre

Arteriosclerosis

Recruiting

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational

Czechia

Participants:18–64 years · 65+ years
Substances:Maridebart Cafraglutide
Sponsor:Amgen Inc.

Contact Research Centre

Cardiac failure

Not recruiting

A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

Investigational

A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

Investigational

Czechia

Participants:18–64 years · 65+ years
Substances:Ziltivekimab
Sponsor:Novo Nordisk A/S

Contact Research Centre

Myocardial infarction

Not recruiting

Study of Orticumab in Adults with Previous Heart Attack and High Coronary Inflammation Measured by CT Scan

Investigational

Study of Orticumab in Adults with Previous Heart Attack and High Coronary Inflammation Measured by CT Scan

Investigational

Czechia

Participants:18–64 years · 65+ years
Sponsor:Abcentra LLC

Contact Research Centre

Arteriosclerosis

Not recruiting

Study on the Effect of Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease Not Adequately Managed by Current Lipid-Lowering Treatments

Investigational

Study on the Effect of Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease Not Adequately Managed by Current Lipid-Lowering Treatments

Investigational

Czechia

Participants:18–64 years · 65+ years
Substances:Obicetrapib
Sponsor:NewAmsterdam Pharma B.V.

Contact Research Centre

Obesity

Not recruiting

Weight loss in adults with obesity (with or without type 2 diabetes) using cagrilintide and semaglutide: a study of two dose levels versus semaglutide alone

InvestigationalNo placebo